S&P 500   2,472.65 (-4.33%)
DOW   21,025.66 (-4.07%)
QQQ   183.62 (-3.56%)
AAPL   243.49 (-4.25%)
FB   160.42 (-3.82%)
MSFT   152.91 (-3.04%)
GOOGL   1,109.47 (-4.52%)
AMZN   1,908.35 (-2.12%)
CGC   13.56 (-6.03%)
NVDA   251.96 (-4.42%)
BABA   187.19 (-3.75%)
MU   40.23 (-4.35%)
GE   7.19 (-9.33%)
TSLA   495.32 (-5.47%)
AMD   44.56 (-2.02%)
T   27.95 (-4.12%)
F   4.43 (-8.48%)
NFLX   362.34 (-3.50%)
BAC   19.76 (-6.97%)
GILD   72.89 (-2.50%)
PRI   83.89 (-5.69%)
DIS   94.73 (-1.94%)
S&P 500   2,472.65 (-4.33%)
DOW   21,025.66 (-4.07%)
QQQ   183.62 (-3.56%)
AAPL   243.49 (-4.25%)
FB   160.42 (-3.82%)
MSFT   152.91 (-3.04%)
GOOGL   1,109.47 (-4.52%)
AMZN   1,908.35 (-2.12%)
CGC   13.56 (-6.03%)
NVDA   251.96 (-4.42%)
BABA   187.19 (-3.75%)
MU   40.23 (-4.35%)
GE   7.19 (-9.33%)
TSLA   495.32 (-5.47%)
AMD   44.56 (-2.02%)
T   27.95 (-4.12%)
F   4.43 (-8.48%)
NFLX   362.34 (-3.50%)
BAC   19.76 (-6.97%)
GILD   72.89 (-2.50%)
PRI   83.89 (-5.69%)
DIS   94.73 (-1.94%)
S&P 500   2,472.65 (-4.33%)
DOW   21,025.66 (-4.07%)
QQQ   183.62 (-3.56%)
AAPL   243.49 (-4.25%)
FB   160.42 (-3.82%)
MSFT   152.91 (-3.04%)
GOOGL   1,109.47 (-4.52%)
AMZN   1,908.35 (-2.12%)
CGC   13.56 (-6.03%)
NVDA   251.96 (-4.42%)
BABA   187.19 (-3.75%)
MU   40.23 (-4.35%)
GE   7.19 (-9.33%)
TSLA   495.32 (-5.47%)
AMD   44.56 (-2.02%)
T   27.95 (-4.12%)
F   4.43 (-8.48%)
NFLX   362.34 (-3.50%)
BAC   19.76 (-6.97%)
GILD   72.89 (-2.50%)
PRI   83.89 (-5.69%)
DIS   94.73 (-1.94%)
S&P 500   2,472.65 (-4.33%)
DOW   21,025.66 (-4.07%)
QQQ   183.62 (-3.56%)
AAPL   243.49 (-4.25%)
FB   160.42 (-3.82%)
MSFT   152.91 (-3.04%)
GOOGL   1,109.47 (-4.52%)
AMZN   1,908.35 (-2.12%)
CGC   13.56 (-6.03%)
NVDA   251.96 (-4.42%)
BABA   187.19 (-3.75%)
MU   40.23 (-4.35%)
GE   7.19 (-9.33%)
TSLA   495.32 (-5.47%)
AMD   44.56 (-2.02%)
T   27.95 (-4.12%)
F   4.43 (-8.48%)
NFLX   362.34 (-3.50%)
BAC   19.76 (-6.97%)
GILD   72.89 (-2.50%)
PRI   83.89 (-5.69%)
DIS   94.73 (-1.94%)
Log in

NASDAQ:CFMS - ConforMIS Stock Price, Forecast & News

$0.60
-0.04 (-6.30 %)
(As of 04/1/2020 02:29 PM ET)
Today's Range
$0.59
Now: $0.60
$0.65
50-Day Range
$0.56
MA: $0.82
$1.12
52-Week Range
$0.50
Now: $0.60
$4.83
Volume285,177 shs
Average Volume621,389 shs
Market Capitalization$42.58 million
P/E RatioN/A
Dividend YieldN/A
Beta2.26
Conformis, Inc., a medical technology company, develops, manufactures, and sells joint replacement implants. The company offers customized knee replacement products, including iTotal CR, a cruciate-retaining product; iTotal PS, a posterior cruciate ligament substituting product; iDuo, a customized bicompartmental knee replacement system; and iUni, a customized unicompartmental knee replacement product to treat the medial or lateral compartment of the knee. It also provides Conformis Hip System, a hip replacement product; and iJigs, a customized single-use patient-specific instrumentation. The company markets and sells its products to hospitals and other medical facilities through sales force, independent sales representatives, and distributors in the United States, Germany, the United Kingdom, Austria, Ireland, Switzerland, Singapore, Hong Kong, Malaysia, Monaco, Hungary, Spain, and Australia Conformis, Inc. was founded in 2004 and is headquartered in Billerica, Massachusetts.
Read More
ConforMIS logo

Industry, Sector and Symbol

Industry Surgical appliances & supplies
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CFMS
CUSIPN/A
Phone781-345-9001

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$77.43 million
Book Value$0.24 per share

Profitability

Net Income$-28,480,000.00

Miscellaneous

Employees262
Market Cap$42.58 million
Next Earnings Date5/6/2020 (Estimated)
OptionableNot Optionable

Receive CFMS News and Ratings via Email

Sign-up to receive the latest news and ratings for CFMS and its competitors with MarketBeat's FREE daily newsletter.


ConforMIS (NASDAQ:CFMS) Frequently Asked Questions

How has ConforMIS's stock been impacted by COVID-19 (Coronavirus)?

ConforMIS's stock was trading at $0.66 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, CFMS shares have decreased by 9.8% and is now trading at $0.5950. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of ConforMIS?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ConforMIS in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for ConforMIS.

When is ConforMIS's next earnings date?

ConforMIS is scheduled to release its next quarterly earnings announcement on Wednesday, May 6th 2020. View our earnings forecast for ConforMIS.

How were ConforMIS's earnings last quarter?

ConforMIS Inc (NASDAQ:CFMS) issued its earnings results on Monday, March, 2nd. The medical instruments supplier reported ($0.08) earnings per share for the quarter, beating the consensus estimate of ($0.10) by $0.02. The medical instruments supplier earned $19.89 million during the quarter, compared to analysts' expectations of $19.91 million. ConforMIS had a negative return on equity of 121.27% and a negative net margin of 36.78%. View ConforMIS's earnings history.

What guidance has ConforMIS issued on next quarter's earnings?

ConforMIS updated its fourth quarter 2019 Pre-Market earnings guidance on Tuesday, January, 14th. The company provided EPS guidance of for the period. The company issued revenue guidance of $19.9-19.9 million, compared to the consensus revenue estimate of $20.21 million.

What price target have analysts set for CFMS?

3 Wall Street analysts have issued 12-month price objectives for ConforMIS's stock. Their forecasts range from $2.00 to $4.00. On average, they expect ConforMIS's share price to reach $3.00 in the next twelve months. This suggests a possible upside of 404.2% from the stock's current price. View analysts' price targets for ConforMIS.

What are Wall Street analysts saying about ConforMIS stock?

Here are some recent quotes from research analysts about ConforMIS stock:
  • 1. According to Zacks Investment Research, "ConforMIS, Inc. is a medical technology company which develops, manufacture and sells joint replacement implants. The Company's iFit technology platform consists of iFit Design, iFit Printing and iFit Just-in-Time Delivery. It operates primarily in the United States, Germany and the United Kingdom. The Company serves orthopedic surgeons, hospitals and other medical facilities and patients. ConforMIS, Inc. is based in Bedford, United States. " (3/31/2020)
  • 2. BTIG Research analysts commented, "$3 PT on Improving Trends We maintain our Buy rating and $3 PT following 1Q19 results which came in slightly ahead of expectations. Revenue of $20.6M compared favorably to BTIG/Street estimates of $20.0M/$20.1M. Noticeably CFMS saw encouraging uptake with both iTotal PS (+29% xFx) and iTotal Hip (still in the early stages of launch). GMs continued their upward trajectory, increasing 290 bps Y/Y to 47.6%. We believe CFMS’s worst days are behind it and the company is entering into a phase of improved and steady LSD growth driven by existing and recently launched products which give a growing distributor base a full recon line to sell. Recon surgery is clearly moving rapidly towards robotics but CFMS is going against the grain with an alternative option that may appeal to a group of surgeons who don’t want to be tied to a robotic system." (5/2/2019)

Has ConforMIS been receiving favorable news coverage?

News headlines about CFMS stock have trended extremely negative on Wednesday, according to InfoTrie Sentiment. The research firm ranks the sentiment of media coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. ConforMIS earned a coverage optimism score of -4.0 on InfoTrie's scale. They also assigned news stories about the medical instruments supplier a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the company's share price in the immediate future. View the latest news aboutConforMIS.

Are investors shorting ConforMIS?

ConforMIS saw a increase in short interest in the month of February. As of February 28th, there was short interest totaling 4,010,000 shares, an increase of 21.5% from the February 13th total of 3,300,000 shares. Based on an average daily trading volume, of 616,800 shares, the short-interest ratio is presently 6.5 days. Approximately 6.2% of the shares of the stock are sold short. View ConforMIS's Current Options Chain.

Who are some of ConforMIS's key competitors?

What other stocks do shareholders of ConforMIS own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ConforMIS investors own include Martin Midstream Partners (MMLP), NVIDIA (NVDA), Micron Technology (MU), Advanced Micro Devices (AMD), Cisco Systems (CSCO), AT&T (T), Alibaba Group (BABA), Pfizer (PFE), Intel (INTC) and Starbucks (SBUX).

Who are ConforMIS's key executives?

ConforMIS's management team includes the following people:
  • Mr. Mark A. Augusti, CEO, Pres & Director (Age 53)
  • Mr. Paul S. Weiner CPA, CFO & Treasurer (Age 55)
  • Ms. Patricia A. Davis J.D., Chief Legal Officer, Gen. Counsel & Corp. Sec. (Age 53)
  • Mr. Ed Kilgallen, VP of Operations
  • Ms. Lisa M. Donnelly, Sr. VP of Global Marketing

When did ConforMIS IPO?

(CFMS) raised $135 million in an initial public offering on Wednesday, July 1st 2015. The company issued 9,000,000 shares at $14.00-$16.00 per share. J.P. Morgan and Deutsche Bank Securities served as the underwriters for the IPO and Wells Fargo Securities and Canaccord Genuity were co-managers.

What is ConforMIS's stock symbol?

ConforMIS trades on the NASDAQ under the ticker symbol "CFMS."

How do I buy shares of ConforMIS?

Shares of CFMS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is ConforMIS's stock price today?

One share of CFMS stock can currently be purchased for approximately $0.60.

How big of a company is ConforMIS?

ConforMIS has a market capitalization of $42.58 million and generates $77.43 million in revenue each year. The medical instruments supplier earns $-28,480,000.00 in net income (profit) each year or ($0.44) on an earnings per share basis. ConforMIS employs 262 workers across the globe. View additional information about ConforMIS.

What is ConforMIS's official website?

The official website for ConforMIS is http://www.conformis.com/.

How can I contact ConforMIS?

ConforMIS's mailing address is 600 TECHNOLOGY PARK DRIVE, BILLERICA MA, 01821. The medical instruments supplier can be reached via phone at 781-345-9001 or via email at [email protected]


MarketBeat Community Rating for ConforMIS (NASDAQ CFMS)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  337 (Thanks for Voting!)
Underperform Votes:  280 (Thanks for Voting!)
Total Votes:  617
MarketBeat's community ratings are surveys of what our community members think about ConforMIS and other stocks. Vote "Outperform" if you believe CFMS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CFMS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 4/1/2020 by MarketBeat.com Staff

Featured Article: Fibonacci Channel

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel